Latest News-VOLITIONRX LTD Mediaroom_Page

Volition Achieves CE Mark for Nu.Q® NETs Test

to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022...

2022-05-31 20:00 3168

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:3...

2022-05-12 04:10 3396

VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update

Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern Time Capital Markets Day Frid...

2022-05-06 20:00 4201

VolitionRx Limited to Host Capital Markets Day on Friday May 13

AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a ...

2022-05-05 20:03 1294

Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare

AUSTIN, Texas, April 25, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")...

2022-04-25 20:00 2704

Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),...

2022-04-06 20:00 2794

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care

AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")...

2022-03-29 20:00 2024

VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update

Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 2...

2022-03-29 04:25 1980

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), ...

2022-01-20 21:30 3591

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

* SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor ...

2021-12-16 21:00 2755

VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") t...

2021-11-08 21:30 2588

Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference

* Positive data show Nu.Q® can be used to monitor for disease response and progression including ...

2021-11-04 20:33 2886

VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update

* Strong balance sheet with approximately $27.9 million in cash and cash equivalents * Strength...

2021-08-12 04:10 24816

VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") t...

2021-08-04 20:15 40622

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),...

2021-07-22 20:00 11500

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

* Secured strongest-ever balance sheet with approximately $33.1 million in cash * Strengthened ...

2021-05-12 04:10 5803

VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") to...

2021-05-06 20:15 3477

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")...

2021-03-31 20:30 1766

VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")...

2021-03-30 20:30 2911

VolitionRx Limited Appoints Two New Directors

AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")...

2021-03-30 04:10 3527